Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Taho Pharmaceuticals Ltd. is currently addressing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is concentrated, involving 1 distinct examiner and 1 distinct art unit. This suggests that the company's current patent activity is focused on a specific pharmaceutical innovation rather than a broad array of diverse technologies. Concentrating on 1 distinct art unit allows the company to tailor its arguments to the specific scientific standards prevalent in that area of biotechnology. This approach can lead to efficient interactions with the patent office.
The busiest examiner, LEE, ANDREW P, is assigned 1 busiest examiner pending office action. Since this 1 action is the only one pending for the company, the examiner's specific review style will be the primary factor in the application's progress. Practitioners should focus on the examiner's past rulings to effectively navigate this single pending matter. The company's immediate success in the pharmaceutical sector depends on the resolution of this 1 pending office action under the guidance of this specific examiner. Maintaining a focus on this individual's requirements is essential for securing the company's intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18680142 | APIXABAN FILM PRODUCT AND USES THEREOF | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18680142 | APIXABAN FILM PRODUCT AND USES THEREOF | LEE, ANDREW P | 1691 | §103 | Non-Final OA | — | Pending | May 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTaho Pharmaceuticals Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew P Lee has the most, with 1 of Taho Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
